News | September 23, 2024
DevCo completes strategic capital raise for investment in Medix Biochemica
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
This strategic decision will unlock significant value for our scientific and industrial products business
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Subscribe To Our Newsletter & Stay Updated
